340 related articles for article (PubMed ID: 20142332)
1. Standard and emerging therapies for metastatic differentiated thyroid cancer.
O'Neill CJ; Oucharek J; Learoyd D; Sidhu SB
Oncologist; 2010; 15(2):146-56. PubMed ID: 20142332
[TBL] [Abstract][Full Text] [Related]
2. Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.
Kojic KL; Kojic SL; Wiseman SM
Expert Rev Anticancer Ther; 2012 Mar; 12(3):345-57. PubMed ID: 22369326
[TBL] [Abstract][Full Text] [Related]
3. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Ricarte-Filho JC; Ryder M; Chitale DA; Rivera M; Heguy A; Ladanyi M; Janakiraman M; Solit D; Knauf JA; Tuttle RM; Ghossein RA; Fagin JA
Cancer Res; 2009 Jun; 69(11):4885-93. PubMed ID: 19487299
[TBL] [Abstract][Full Text] [Related]
4. Emerging Therapies for Radioactive Iodine Refractory Thyroid Cancer.
Kirtane K; Roth MY
Curr Treat Options Oncol; 2020 Feb; 21(3):18. PubMed ID: 32048061
[TBL] [Abstract][Full Text] [Related]
5. Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer.
Fullmer T; Cabanillas ME; Zafereo M
Front Endocrinol (Lausanne); 2021; 12():720723. PubMed ID: 34335481
[TBL] [Abstract][Full Text] [Related]
6. Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer.
Ibrahim EY; Busaidy NL
Curr Opin Oncol; 2017 Mar; 29(2):151-158. PubMed ID: 28141684
[TBL] [Abstract][Full Text] [Related]
7. The Treatment of Well-Differentiated Thyroid Carcinoma.
Paschke R; Lincke T; Müller SP; Kreissl MC; Dralle H; Fassnacht M
Dtsch Arztebl Int; 2015 Jun; 112(26):452-8. PubMed ID: 26205749
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.
Oh JM; Ahn BC
Theranostics; 2021; 11(13):6251-6277. PubMed ID: 33995657
[TBL] [Abstract][Full Text] [Related]
9. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
[No Abstract] [Full Text] [Related]
10. New directions in the systemic treatment of metastatic thyroid cancer.
Higgins MJ; Forastiere A; Marur S
Oncology (Williston Park); 2009 Aug; 23(9):768-75. PubMed ID: 19777762
[TBL] [Abstract][Full Text] [Related]
11. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
[No Abstract] [Full Text] [Related]
12. Current Concepts in the Molecular Genetics and Management of Thyroid Cancer: An Update for Radiologists.
Kelil T; Keraliya AR; Howard SA; Krajewski KM; Braschi-Amirfarzan M; Hornick JL; Ramaiya NH; Tirumani SH
Radiographics; 2016; 36(5):1478-93. PubMed ID: 27618325
[TBL] [Abstract][Full Text] [Related]
13. Unusual metastases from differentiated thyroid cancers: A multicenter study in Korea.
Yoon JH; Jeon MJ; Kim M; Hong AR; Kim HK; Shin DY; Kim BH; Kim WB; Shong YK; Kang HC
PLoS One; 2020; 15(8):e0238207. PubMed ID: 32841270
[TBL] [Abstract][Full Text] [Related]
14. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
15. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
16. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
Liu J; Liu Y; Lin Y; Liang J
Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes and risk stratification for papillary thyroid carcinoma presenting with distant metastasis before the era of tyrosine kinase inhibitors.
Matsuzu K; Sugino K; Masudo K; Mori K; Ono R; Yamazaki H; Masaki C; Akaishi J; Kiyomi Yamada H; Tomoda C; Suzuki A; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Takami H; Ito K
Endocr J; 2020 Aug; 67(8):869-876. PubMed ID: 32350192
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
[TBL] [Abstract][Full Text] [Related]
19. Radioiodine therapy of advanced differentiated thyroid cancer: clinical considerations and multidisciplinary approach.
Giovanella L; Scappaticcio L
Q J Nucl Med Mol Imaging; 2019 Sep; 63(3):229-234. PubMed ID: 31271270
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Cortas C; Charalambous H
Life (Basel); 2023 Dec; 14(1):. PubMed ID: 38255638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]